Explore These Critical Case Reviews:

• Frontline Metastatic Colorectal Cancer:
  Unresectable Liver Metastases
• Frontline Metastatic Colorectal Cancer:
  Resectable Liver Metastases
• Adjuvant Treatment for Colorectal Cancer:
  Stage II and Stage III
• Refractory Colorectal Cancer

Educational Objectives

After participating in this program, participants should be able to:

• Review cases of patients with different stages of colorectal cancer, and reinforce an understanding of the decision-making process that goes into the formulation of evidence-based treatment plans.
• Demonstrate an understanding of the new standard in adjuvant treatment for stage III disease and the benefi t of adjuvant treatment for stage II disease.
• Incorporate into practice all treatment options for patients with advanced colorectal cancer. Understand that the selected initial therapy infl uences the sequence of treatment regimens. (Special consideration must be taken in fi nding the appropriate first step in the medical management of advanced colorectal cancer.)
• Assimilate the variables related to comorbidities, prior toxicities, and the initial response (or lack of response to the fi rst-line approach) in the selection of secondline treatments.
• Review the variables that go into dosing and possible toxicities that colorectal cancer patients may face from chemotherapy, and demonstrate ways to counteract these effects.
• Reinforce the importance of the “team approach” when managing the resectable or potentially resectable patient.

Who Will Benefit

Community-based oncologists, hematologists/oncologists, nurse practitioners and nurses.

Accreditation

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of CME LLC and The Oncology Group. CME LLC is accredited by the ACCME to provide continuing medical education for physicians.

CME LLC designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™.

Physicians should only claim credit commensurate with the extent of their participation in the activity. Physicians not licensed in the United States who participate in this CME activity are eligible for AMA PRA Category 1 Credit(s)™.